Quick Answer
Anika Therapeutics, Inc. reported R&D Expense of $25.77 million for fiscal year 2025.
Anika Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $25.77M | +0.9% |
| 2024 | $25.54M | +17.4% |
| 2023 | $21.76M | +18.8% |
| 2022 | $18.32M | -33.0% |
| 2021 | $27.33M | +16.6% |
| 2020 | $23.43M | +40.6% |
| 2019 | $16.66M | -8.4% |
| 2018 | $18.19M | -3.2% |
| 2017 | $18.79M | +75.1% |
| 2016 | $10.73M | +19.4% |
| 2015 | $8.99M | +10.4% |
| 2014 | $8.14M | +15.4% |
| 2013 | $7.06M | +31.0% |
| 2012 | $5.39M | -12.7% |
| 2011 | $6.17M | -10.3% |
| 2010 | $6.87M | -16.0% |
| 2009 | $8.18M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.95M | +16.8% | +10.0% |
| June 30, 2025 | $6.31M | -5.5% | +4.2% |
| March 31, 2025 | $6.06M | -5.5% | +1.9% |
| September 30, 2024 | $5.95M | -23.7% | -11.0% |
| June 30, 2024 | $6.68M | -25.0% | +4.3% |
| March 31, 2024 | $6.41M | -23.7% | -17.7% |
| September 30, 2023 | $7.79M | +6.7% | -12.6% |
| June 30, 2023 | $8.91M | +27.8% | +6.1% |
- Anika Therapeutics, Inc. showed an increase of +0.9% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, Anika Therapeutics, Inc.’s r&d expense has grown by 215.0% (from $8.18 million to $25.77 million).
- The most recent figure is from Anika Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: